ArticleInternational journal of clinical oncology2023
Cancer may accelerate locomotive syndrome and deteriorate quality of life: a single-centre cross-sectional study of locomotive syndrome in cancer patients.
Article in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Historical contributions and future horizons of Japanese orthopaedic oncology: from surgical innovation to nationwide collaborations.International orthopaedics · 2026Article
- Locomotive syndrome: history, current concepts, and future perspectives.International orthopaedics · 2026Review
- Characteristics of Inpatient Falls and Factors Associated with Fall-Related Fractures and Recurrent Falls in a Japanese University Hospital.Medical sciences (Basel, Switzerland) · 2026Article
- Subchondral Insufficiency Fracture of the Femoral Head in a Terminal Cancer Patient Treated by Total Hip Arthroplasty.Journal of orthopaedic case reports · 2026Article
- Article
- Correlation between musculoskeletal system function and pre-depressive states in elderly cancer patients: A single-center cross-sectional study.World journal of psychiatry · 2025Article
- Article
- Usefulness of the Phase Angle in Evaluating Locomotive Syndrome in Cancer Patients.Journal of clinical medicine · 2025Article
- Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.Current oncology (Toronto, Ont.) · 2025Article
- Correlation between metabolic syndrome indicators and locomotive syndrome in Chinese geriatric oncology inpatients.Frontiers in medicine · 2025Article
- The prevalence and correlation of cancer-related fatigue and locomotive syndrome in geriatric cancer patients.PloS one · 2025Article
- Reliability and validity tests of the Chinese version of the Geriatric Locomotive Function Scale (GLFS-25) in tumor survivors.Heliyon · 2024Article
- Current status and risk determinants of locomotive syndrome in geriatric cancer survivors in China-a single-center cross-sectional survey.Frontiers in public health · 2024Article
- A new era in the management of spinal metastasis.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThanks to recent advancement in cancer treatment, an increasing number of cancer patients are expected to live longer with cancer. The ambulatory ability is essential for cancer patients to spend their own independent lives, but locomotive syndrome (LS), a condition of reduced mobility due to impairment of locomotive organs, in cancer patients has been seldom examined.
methodsThis was a single-institutional cross-sectional study. Cancer patients receiving cancer therapy between April 2020 and March 2021 were asked to participate. LS was classified as stage 0-3, and compared with their performance status (PS). Physical component summary (PCS) and mental component summary (MCS) were calculated from the results of Short Form-8. Logistic regression analysis was performed to identify risk factors for LS stage 3.
resultsOne hundred and seventy-six cancer patients were included. The rate of LS was 96.0%. That of LS stage 3 was 40.9% and as high as 29.7% even if limited to those with PS 0. The mean PCS and MCS were both inferior to the national averages. PCS decreased as the LS stage advanced. Old age and underweight were revealed as independent risk factors for LS stage 3.
conclusionsThe ratio of LS in cancer patients was extremely high, and the LS stage correlated with physical QOL. Even those with PS 0 can have severe LS; thus, LS can be a sensitive detector of physical disability of cancer patients than PS. The improvement of LS can be a key to the preservation of their ADL and QOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.